Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 9:10 PM
Ignite Modification Date: 2025-12-25 @ 7:00 PM
NCT ID: NCT05395104
Description: None
Frequency Threshold: 0
Time Frame: Day -1 through Day 23
Study: NCT05395104
Study Brief: A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Cefiderocol Plus Midazolam A total of 2 doses of midazolam and 45 doses of cefiderocol were administered to each participant per specified dosing schedule. 0 None 0 14 11 14 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Abdominal pain SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 25.0 View
Diarrhoea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 25.0 View
Nausea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 25.0 View
Infusion site extravasation SYSTEMATIC_ASSESSMENT General disorders MedDRA 25.0 View
Infusion site pain SYSTEMATIC_ASSESSMENT General disorders MedDRA 25.0 View
Infusion site phlebitis SYSTEMATIC_ASSESSMENT General disorders MedDRA 25.0 View
Catheter site pain SYSTEMATIC_ASSESSMENT General disorders MedDRA 25.0 View
Chills SYSTEMATIC_ASSESSMENT General disorders MedDRA 25.0 View
Infusion site dermatitis SYSTEMATIC_ASSESSMENT General disorders MedDRA 25.0 View
Infusion site inflammation SYSTEMATIC_ASSESSMENT General disorders MedDRA 25.0 View
Non-cardiac chest pain SYSTEMATIC_ASSESSMENT General disorders MedDRA 25.0 View
Pyrexia SYSTEMATIC_ASSESSMENT General disorders MedDRA 25.0 View
Vessel puncture site haemorrhage SYSTEMATIC_ASSESSMENT General disorders MedDRA 25.0 View
Drug hypersensitivity SYSTEMATIC_ASSESSMENT Immune system disorders MedDRA 25.0 View
Vulvovaginal candidiasis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 25.0 View
Blood lactate dehydrogenase increased SYSTEMATIC_ASSESSMENT Investigations MedDRA 25.0 View
Transaminases increased SYSTEMATIC_ASSESSMENT Investigations MedDRA 25.0 View
Neck pain SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA 25.0 View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 25.0 View
Somnolence SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 25.0 View
Dizziness SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 25.0 View
Presyncope SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 25.0 View
Cough SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA 25.0 View
Epistaxis SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA 25.0 View
Rhinorrhoea SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA 25.0 View
Urticaria SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA 25.0 View